Allyson Guidroz - 14 Aug 2025 Form 4 Insider Report for AMEDISYS INC (AMED)

Reporting relationship: Chief Accounting Officer
Issuer ticker: AMED
Reported as of: 14 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2025, 16:02:05 UTC
Prior SEC filing: 08 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Guckert Griffin, pursuant to a power of attorney

Key filing fact

Allyson Guidroz filed Form 4 for AMEDISYS INC (AMED) on 14 Aug 2025.

Key facts

This page summarizes Allyson Guidroz's Form 4 filing for AMEDISYS INC (AMED).
7 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 14 Aug 2025, 16:02.

Change

Previous filing in this sequence was filed on 08 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001991938 Primary reporting owner

Guidroz Allyson

Relationship: Chief Accounting Officer
Address: 3854 AMERICAN WAY , SUITE A, BATON ROUGE
Signature: /s/ Jennifer Guckert Griffin, pursuant to a power of attorney
Signature date: 14 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMED transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -898
Change %: -9.5%
Price
Shares after: 8,574
Date: 14 Aug 2025
Ownership: Direct
Footnotes: F1

AMED transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -8,574
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Footnotes: F2

AMED transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -2
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: By 401(k) Plan
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -272
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 272
Exercise price: $95.76
Footnotes: F4, F5

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -640
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 640
Exercise price: $132.41
Footnotes: F4, F5

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -563
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 563
Exercise price: $214.74
Footnotes: F4, F5

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -590
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 590
Exercise price: $264.00
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Allyson Guidroz is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.

Footnote F2

Pursuant to the Merger Agreement, outstanding restricted stock units ("RSUs") of the Issuer were automatically converted into UnitedHealth Group RSUs, calculated by multiplying the number of Issuer RSUs by the quotient obtained by dividing the Per Share Merger Consideration by the volume-weighted average of the closing sale price per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date (the "Equity Award Exchange Ratio"), which continue to be subject to the same terms and conditions (including vesting and settlement terms) as were applicable to the Issuer RSUs.

Footnote F3

As of the Effective Time, each of the shares of the Issuer's Common Stock that the Reporting Person previously reported as beneficially owned under the Issuer's 401(k) plan was converted into the right to receive the Per Share Merger Consideration.

Footnote F4

These options are fully vested.

Footnote F5

In connection with the Merger, stock option awards of the Issuer were automatically converted into an option to purchase a number of shares of common stock of UnitedHealth Group equal to the product of (i) the number of shares of Common Stock subject to the Issuer stock option multiplied by (ii) Equity Award Exchange Ratio, at an exercise price per share equal to (i) the exercise price of the Issuer stock option divided by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group options will continue to be subject to the same terms and conditions as were applicable to the existing Issuer stock option.